Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals



Availability: In stock

Special Price $ 320

BRAND : Tasigna
STRENGTH : 150mg & 200mg
INGREDIENT : Anticancer-CaNcer-Treatment-Novartis-Nilotinib-150mg-Tasigna
COUNT : 28 Tablets

Description of Tasigna

Brand name: Tasigna Active ingredient: Nilotinib hydrochloride monohydrate Strength of the content: 150MG Mfg: Novartis pharmaceuticals Category: Anti-neoplastic drug Description: Nilotinib is a targeted cancer medicine (biological therapy) and also called Tasigna, the trade name of nilotinib Tasigna is cancer drugs, which interfere with growth of the cancer cells. Tasigna is a prescription medicine, which is used under the knowledge of medical oncologist. The safety and efficacy of the medicine Tasigna in children younger than 1 year has not been established Tasigna is comes under the group of kinase inhibitors.

Pharmacology of Tasigna

Mechanism of action: CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene Tasigna (nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. Tasigna bind to the ATP-binding site of BCR-ABL protein Tasigna prohibits multiplication of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML Pharmacokinetic: Absorption: The bioavailability of Tasigna tablets are about 50% The peak plasma concentration of Tasigna tablet is occurred within 3 hours after administration. Effect of food: While compared to fasted patient, the effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal Distribution: The serum protein binding of the Tasigna is approximately 98% The blood to serum ratio of nilotinib is 0.68 Metabolism: Tasigna is metabolized through CYP3A4 mediated oxidation Nilotinib is the prime circulating component in the blood stream Elimination: The terminal half life period of Tablet Tasigna is approximately 17 hours The mean apparent clearance value is 29L/hr

Indication of Tasigna

Tasigna tablets are primarily indicated in the conditions like; Adults with chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib

Dose & Dosage's of Tasigna

Generally the recommended dose of Tablet Tasigna should be taken as twice daily at time intervals of 12 hours. Tasigna must be taken on an empty stomach Food should not be taken for at least 1 hour after the dose is taken or 2 hours before the dose is taken The patients, who are unable to taken the Tasigna capsules, should be dispersed in one teaspoon of applesauce. This mixture should be taken immediately within 15 minutes Tasigna should be concomitant with hematopoietic growth factors such as erythropoietin or G-CSF Also with hydroxyurea or anagrelide Dosage in adult patients with Philadelphia positive CML-CP: The prescribed dose of the Tasigna tablet in this condition is 300mg should be given orally as twice daily. With resistant or intolerant Philadelphia positive CML-CP and CML-AP: The prescribed dose is 400mg should be administered as orally twice daily In pediatrics: The recommended dose 230mg/m2 should be given orally twice daily BSA (body surface area) Single dose Total daily dose Up to 0.32 m2 50 mg 100mg 0.33 to 0.54 m2 100mg 200mg 0.55 to 0.76 m2 150mg 300mg 0.77 to 0.97 m2 200mg 400mg 0.98 to 1.19 m2 250mg 500mg 1.20 to 1.41 m2 300mg 600mg 1.42 to 1.63 m2 350mg 700mg ≥1.64 m2 400mg 800mg The maximum dose of Tablet Tasigna is 400mg.

Side Effects of Tasigna

Skin: Rash, Pruritus, alopecia, dry skin GIT: Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia Nerve system: Headache, dizziness General: Fatigue, pyrexia, asthenia, peripheral edema, face edema Muscle: Myalgia, arthralgia, muscle spasm, pain in extremity, back pain Pulmonary: Cough, oropharyngeal pain, dyspnea Infections & infestations: Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis Eye: Eyelid edema, periorbital edema Psychiatric: Insomnia Vascular: Hypertension

Contraindication of Tasigna

Tasigna do not used in the patients who are having; Hypokalemia Hypomagnesemia Long QT syndrome

Drug Interaction of Tasigna

Tasigna While concomitant with strong CYP3A inhibitors leads to increase nilotinib concentrations compared to while using Tasigna alone Tasigna Concomitant with strong CYP3A inducer leads to reduce nilotinib concentration Tasigna With proton pump inhibitors: reduce Tasigna efficacy Avoid concomitant of Tasigna with drugs that may prolong the QT interval like anti-arrhythmic drugs

Precaution of Tasigna

Tasigna may cause thrombocytopenia, neutropenia and anemia, so check blood counts periodically to reduce these complications Care should be take while using Tasigna in patient who are suffered with Hypokalemia Hypomagnesemia Long QT syndrome Pancreatitis and elevated lipase Hepatotoxicity Electrolyte abnormalities Tumor lysis syndrome

Usage & Safety profile of Tasigna Pregnancy & Lactation

Pregnancy category: D Tasigna should not be used in pregnancy condition and women who become pregnant Tasigna not recommended in breastfeeding mothers

Storage of Tasigna

Tasigna tablets should be stored at room temperature between 68oF to 77oF (20oC to 25oC)